vs

Side-by-side financial comparison of MEDIFAST INC (MED) and SMARTFINANCIAL INC. (SMBK). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $53.8M, roughly 1.4× SMARTFINANCIAL INC.). Over the past eight quarters, SMARTFINANCIAL INC.'s revenue compounded faster (15.4% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

SmartFinancial Inc. is a U.S.-based bank holding company that operates its wholly owned subsidiary SmartBank. It offers a full range of retail and commercial banking products including deposit accounts, personal and business loans, mortgage services, and wealth management solutions, primarily serving individual customers and small-to-medium enterprises across the Southeastern United States.

MED vs SMBK — Head-to-Head

Bigger by revenue
MED
MED
1.4× larger
MED
$75.1M
$53.8M
SMBK
Faster 2-yr revenue CAGR
SMBK
SMBK
Annualised
SMBK
15.4%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
MED
MED
SMBK
SMBK
Revenue
$75.1M
$53.8M
Net Profit
$13.7M
Gross Margin
69.4%
Operating Margin
-10.4%
Net Margin
25.4%
Revenue YoY
-36.9%
Net Profit YoY
21.6%
EPS (diluted)
$-1.64
$0.81

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
SMBK
SMBK
Q1 26
$53.8M
Q4 25
$75.1M
$53.3M
Q3 25
$89.4M
$51.1M
Q2 25
$105.6M
$49.2M
Q1 25
$115.7M
$46.8M
Q4 24
$119.0M
$46.8M
Q3 24
$140.2M
$44.2M
Q2 24
$168.6M
$40.4M
Net Profit
MED
MED
SMBK
SMBK
Q1 26
$13.7M
Q4 25
$13.7M
Q3 25
$-2.3M
$13.7M
Q2 25
$2.5M
$11.7M
Q1 25
$-772.0K
$11.3M
Q4 24
$9.6M
Q3 24
$1.1M
$9.1M
Q2 24
$-8.2M
$8.0M
Gross Margin
MED
MED
SMBK
SMBK
Q1 26
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Operating Margin
MED
MED
SMBK
SMBK
Q1 26
Q4 25
-10.4%
31.3%
Q3 25
-4.6%
33.2%
Q2 25
-1.0%
29.0%
Q1 25
-1.1%
29.0%
Q4 24
0.6%
26.5%
Q3 24
1.5%
24.3%
Q2 24
-4.7%
25.6%
Net Margin
MED
MED
SMBK
SMBK
Q1 26
25.4%
Q4 25
25.7%
Q3 25
-2.5%
26.8%
Q2 25
2.3%
23.8%
Q1 25
-0.7%
24.0%
Q4 24
20.6%
Q3 24
0.8%
20.7%
Q2 24
-4.8%
19.8%
EPS (diluted)
MED
MED
SMBK
SMBK
Q1 26
$0.81
Q4 25
$-1.64
$0.81
Q3 25
$-0.21
$0.81
Q2 25
$0.22
$0.69
Q1 25
$-0.07
$0.67
Q4 24
$0.08
$0.57
Q3 24
$0.10
$0.54
Q2 24
$-0.75
$0.48

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
SMBK
SMBK
Cash + ST InvestmentsLiquidity on hand
$167.3M
$346.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$198.9M
$562.2M
Total Assets
$248.0M
$5.9B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
SMBK
SMBK
Q1 26
$346.1M
Q4 25
$167.3M
$464.4M
Q3 25
$173.5M
$557.1M
Q2 25
$162.7M
$365.1M
Q1 25
$164.6M
$423.0M
Q4 24
$162.3M
$387.6M
Q3 24
$170.0M
$192.9M
Q2 24
$163.5M
$342.8M
Total Debt
MED
MED
SMBK
SMBK
Q1 26
Q4 25
Q3 25
$1.3M
Q2 25
$7.0M
Q1 25
$7.6M
Q4 24
$8.1M
Q3 24
$9.0M
Q2 24
$12.7M
Stockholders' Equity
MED
MED
SMBK
SMBK
Q1 26
$562.2M
Q4 25
$198.9M
$552.4M
Q3 25
$214.7M
$538.4M
Q2 25
$216.0M
$519.0M
Q1 25
$211.0M
$505.8M
Q4 24
$210.1M
$491.3M
Q3 24
$207.3M
$489.0M
Q2 24
$205.3M
$472.5M
Total Assets
MED
MED
SMBK
SMBK
Q1 26
$5.9B
Q4 25
$248.0M
$5.9B
Q3 25
$268.2M
$5.8B
Q2 25
$269.3M
$5.5B
Q1 25
$280.0M
$5.4B
Q4 24
$284.2M
$5.3B
Q3 24
$291.2M
$4.9B
Q2 24
$293.5M
$4.9B
Debt / Equity
MED
MED
SMBK
SMBK
Q1 26
Q4 25
Q3 25
0.00×
Q2 25
0.01×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.02×
Q2 24
0.03×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
SMBK
SMBK
Operating Cash FlowLast quarter
$-5.3M
Free Cash FlowOCF − Capex
$-6.6M
FCF MarginFCF / Revenue
-8.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
SMBK
SMBK
Q1 26
Q4 25
$-5.3M
$61.7M
Q3 25
$12.1M
$16.9M
Q2 25
$-3.4M
$14.0M
Q1 25
$3.4M
$14.3M
Q4 24
$-4.9M
$52.7M
Q3 24
$9.1M
$12.4M
Q2 24
$13.1M
$16.5M
Free Cash Flow
MED
MED
SMBK
SMBK
Q1 26
Q4 25
$-6.6M
$59.3M
Q3 25
$10.8M
$16.6M
Q2 25
$-4.8M
$13.2M
Q1 25
$1.9M
$13.4M
Q4 24
$-7.2M
$46.3M
Q3 24
$7.7M
$11.3M
Q2 24
$11.1M
$15.4M
FCF Margin
MED
MED
SMBK
SMBK
Q1 26
Q4 25
-8.8%
111.3%
Q3 25
12.0%
32.4%
Q2 25
-4.5%
26.9%
Q1 25
1.6%
28.5%
Q4 24
-6.1%
98.9%
Q3 24
5.5%
25.7%
Q2 24
6.6%
38.2%
Capex Intensity
MED
MED
SMBK
SMBK
Q1 26
Q4 25
1.8%
4.5%
Q3 25
1.5%
0.6%
Q2 25
1.3%
1.6%
Q1 25
1.3%
2.0%
Q4 24
1.9%
13.7%
Q3 24
1.0%
2.4%
Q2 24
1.1%
2.7%
Cash Conversion
MED
MED
SMBK
SMBK
Q1 26
Q4 25
4.50×
Q3 25
1.23×
Q2 25
-1.36×
1.20×
Q1 25
1.27×
Q4 24
5.47×
Q3 24
8.04×
1.36×
Q2 24
2.07×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MED
MED

Segment breakdown not available.

SMBK
SMBK

Net Interest Income$45.9M85%
Noninterest Income$7.9M15%

Related Comparisons